PAH

14 registered clinical trials studyying PAH — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome NCT07498803	Philipps University Marburg	Phase 2
Not Yet Recruiting	Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients NCT06973382	Beijing Chao Yang Hospital	N/A
Completed	Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated NCT06553924	Humanis Saglık Anonim Sirketi	Phase 1
Completed	Bioequivalence Study of Macitentan and Tadalafil Film-coated Tablets 10 Mg/40 Mg and 'PrOpsynvi®' Macitentan a NCT06553937	Humanis Saglık Anonim Sirketi	Phase 1
Terminated	A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH NCT04084678	United Therapeutics	Phase 3
Unknown	Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmo NCT04309838	University Medicine Greifswald	—
Enrolling By Invitation	A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Exten NCT03683186	United Therapeutics	Phase 3
Terminated	CXA-10 Study in Subjects With Pulmonary Arterial Hypertension NCT04053543	Complexa, Inc.	Phase 2
Completed	A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients NCT03626688	United Therapeutics	Phase 3
Terminated	PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH) NCT03449524	Complexa, Inc.	Phase 2
Completed	Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years NCT02276872	United Therapeutics	Phase 2
Withdrawn	Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Health NCT02149095	United Therapeutics	Phase 1
Withdrawn	Biomarkers in Pulmonary Arterial Hypertension Treated With Nilotinib NCT01320865	The Cleveland Clinic	—
Completed	Pulmonary Hypertension and Imatinib NCT01092897	The Cleveland Clinic	—